UNIVERSITY OF ARIZONA
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial is a funding opportunity from UNIVERSITY OF ARIZONA, up to 6580973, closing April 30, 2027.
Apr 30, 2027
(273d left)Overview
PROJECT SUMMARY/ABSTRACT Therapeutics to prevent, delay and treat Alzheimer’s disease (AD) remain an unmet need. Proposed herein is a regenerative medicine, systems biology approach that targets the regenerative system of the brain while simultaneously activating systems to reduce burden of AD pathology.…